Page last updated: 2024-09-03

n,n-dimethylarginine and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

n,n-dimethylarginine has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 3 studies

Compound Research Comparison

Studies
(n,n-dimethylarginine)
Trials
(n,n-dimethylarginine)
Recent Studies (post-2010)
(n,n-dimethylarginine)
Studies
((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
Trials
((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
Recent Studies (post-2010) ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
2,2162281,2211,459368396

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Oguz, A; Uzunlulu, M1
Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M1
Černe, D; Drevenšek, G; France Štiglic, A; Janić, M; Jerin, A; Lunder, M; Marc, J; Šabovič, M; Skitek, M1

Trials

2 trial(s) available for n,n-dimethylarginine and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

ArticleYear
Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome.
    International heart journal, 2008, Volume: 49, Issue:3

    Topics: Adult; Arginine; Cholesterol; Endothelium, Vascular; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Male; Metabolic Syndrome; Middle Aged; Treatment Outcome

2008
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
    Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:2

    Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke

2011

Other Studies

1 other study(ies) available for n,n-dimethylarginine and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

ArticleYear
Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study.
    Vascular pharmacology, 2017, Volume: 99

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arginine; Blood Pressure; Cholesterol; Coronary Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Male; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Rats, Wistar; Receptor, Endothelin A; Time Factors; Valsartan; Vasodilation

2017